Hinge Health Inc. Class A Common Stock vs Hyperliquid Strategies Inc Common Stock — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Hyperliquid Strategies Inc Common Stock trades at $9.34 (market cap $2.02B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 4.2× Hyperliquid Strategies Inc Common Stock's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Hyperliquid Strategies Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Hyperliquid Strategies Inc Common Stock for 6 Days on average.
| HNGE | PURR | |
|---|---|---|
Market Cap | $8.48B | $2.02B |
Volume | 879,799 | 9,119,303 |
Sector | Health | Financials |
52-Week High | $105.14 | $14.09 |
52-Week Low | $31.17 | $3.10 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.10B | $1.88B |
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
PURR trades at $10.23, down 1.63% over 24 hours, with a bullish technical signal despite recent weakness. The stock shows extreme profitability with a net income margin of 3,229.83% and has beaten earnings estimates for three consecutive quarters. Recent news highlights institutional activity and positive analyst coverage, with a consensus price target of $19.80 implying significant upside.
The outlook is positive given strong earnings momentum and unanimous analyst buy ratings, but risks include high revenue concentration and potential volatility from its asset-heavy business model. The stock's low P/E ratio of 3.18 suggests undervaluation if profitability sustains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →Hyperliquid Strategies is a digital asset treasury company focused on managing a treasury of HYPE tokens, the native digital assets of the Hyperliquid Layer-1 blockchain.
Read more on PURR →